VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, Sci-B-Vac and VBI-2601. It also develops an enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on April 9, 1965 and is headquartered in Cambridge, MA.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company